[Morbidity and mortality in patients undergoing dialysis. Comparison of hemodialysis and peritoneal dialysis. Our experience]. / Morbilità e mortalità in pazienti in dialisi. Confronto fra emodialisi e dialisi peritoneale. Nostra esperienza.

BACKGROUND: We have compared the hemodialysis and peritoneal dialysis populations of our Center for morbidity and mortality, in a retrospective study of six years of activity. METHODS: We enrolled 125 patients (104 patients/year/million inhabitants), who had been in chronic dialysis from 1992 to 1997: 90 (22-90 years old) initiated in hemodialysis and 35 (27-82 years old) in peritoneal dialysis. RESULTS: We have evaluated survival and morbility, as hospitalization/patient/year in both groups. Mortality did not prove significantly different in the two groups. The global average of hospitalization was 8 days/patient/year for hemodialysis and 6 for peritoneal dialysis. CONCLUSIONS: In spite of the short time of observation and the exiguity of numbers, our experience shows that the two methods are equivalent.

[Vascular access for hemodialysis. Our experience in 20 years]. / Accessi vascolari per emodialisi. Nostra esperienza in 20 anni.

A personal series arterio-venous fistulas from the last 20 years is examined. The authors have tried to verify the correctness of their present proctocol which is based on the abolition of those fistulas applied to the anatomic tabac. In fact in some cases they have caused problems of flow, but in other cases they have lasted much longer than any other kind of fistulas.

[Erythropoietin treatment in Piedmont and Valle d'Aosta]. / Il trattamento con eritropoietina in Piemonte e Valle d'Aosta.

The paper reports a study carried out in the Dialysis Centres of Piedmont and the Aosta Valley on the use of erythropoietin in the treatment of anemia in patients undergoing regular dialysis. The efficacy of the drug and collateral and/or undesirable effects were evaluated. It was found that the drug was efficacious in 99.2% of the 342 patients receiving treatment on 30-6-1990, whereas undesirable effects were observed in 14.6% of cases. Data from the Nephrology and Dialysis Service in Asti are also reported.

[Treatment with erythropoietin and iron requirements in dialyzed patients]. / Trattamento con eritropoietina (Epo) e fabbisogno di ferro nel paziente dializzato.

The use of erythropoietin in dialysed patients leads to the gradual depletion of the body's iron reserves. It is important to assay iron blood levels in both patients receiving Epo therapy and those undergoing dialysis without this treatment. The most common method used is to assay ferritinemia, transferrinemia and the transferrin saturation levels. Using a retrospective study it was found that there is no significant difference in the request for iron supplementation in patients receiving Epo treatment compared to a control group not treated with Epo.

[Vascular access for hemodialysis under difficult conditions. Our experience]. / Accessi vascolari per emodialisi in condizioni difficili. Nostra esperienza.

Having examined the causes that lead, on the one hand, to an increased number of vascular accesses in difficult conditions and, on the other, to their reduction and having examined their personal series of vascular accesses for hemodialysis studied between 4 December 1974 to 30 September 1996, and lastly having outlined the correct protocol for the preparation of these accesses, the authors focus on vascular accesses created in difficult conditions, namely the exhaustion of the natural venous and/or arterial bed below the proximal third of the upper limb. In particular, they examine the use of definitive jugular catheters, a more recent and therefore non-standardised method, and conclude that, although not regarded as vascular accesses of first choice, they should no longer be regarded as heroic but, after a short period of learning, they are easy to position and maintain.

[Use of calcium carbonate as an intestinal chelator of phosphorus]. / Utilizzo del calcio carbonato (CaCO3) come chelante intestinale del fosforo.

Fourteen patients undergoing periodic dialysis who had been taking AL(OH)3 as an intestinal chelant of phosphorus have been examined. AL(OH)3 was replaced by CaCO3 for a period of 6 months. At the end of the study, statistically significant reductions were evidenced in alkaline phosphatase, basal serum aluminiaemia and its increase after Desferal test, while the bicarbonates (HCO3) were found to be increased. Statistically non-significant increases were observed in calcaemia, PTH, and pH. It is concluded that the replacement of AL(OH)3 with CaCO3 is effective in controlling phosphoraemia, in diminishing serum concentrations and tissue deposits of Al and in improving uraemic acidosis.

[Description of a case of Zollinger-Ellison syndrome]. / Descrizione di un caso di sindrome di Zollinger-Ellison.

A case of Zollinger-Ellison syndrome with some peculiar aspects is described. The disease started with painless dyspepsia, watery diarrhea, relevant loss of body weight and absence of peptic ulcer. After a steroid treatment performed at home without any rationale, diarrhea stopped totally for 18 months and body weight returned to normal. Subsequently, the disease recurred with more typical clinical characters: juxtapyloric ulcer, increase in serum gastrin levels and positive secretin test, presence of gastrinomas at angiography. The monitoring of gastric pH showed a persistent hyperacidity during medical treatment with H2 and muscarinic antagonists. The localization of gastrinomas was extrapancreatic, at the root of jejunal mesentery. Excellent results were obtained by surgical treatment which consisted in resection of the principal neoplastic masses with total gastrectomy. The patient's general conditions after two years are good.

Long-term ranitidine treatment for the maintenance of duodenal ulcer healing.

The purpose of the present trial was to verify the efficacy and safety of long-term ranitidine treatment (150 mg at bedtime for 1 year) for the maintenance of duodenal ulcer healing in 22 patients following a successful short-term course of therapy with ranitidine at the full dose of 300 mg per day. Of the 16 patients who completed the trial - there were 6 drop-outs - 4 suffered relapses during the year of treatment (25% cumulative recurrence rate), while remission persisted in the remaining 12 patients (75%). Biochemical tests revealed no statistically significant differences in mean fasting serum pepsinogen and trypsinogen as compared to mean basal values. Mean fasting serum gastrin showed a statistically significant rise from 156 +/- 27 S.D. to 258 +/- 110 S.D. pg/ml (p less than 0.01) only at the 12th month of therapy and rapidly returned to normal (162 +/- 34 S.D.) as soon as therapy was discontinued. No side-effects of any consequence were observed.